Chemotherapy enhances cross-presentation of nuclear tumor antigens
| Autor: | Scott A. Fisher, Richard A. Lake, Bruce W. S. Robinson, Chidozie C. Anyaegbu, Kathy Heel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2014 |
| Předmět: |
Tumor Immunology
Immunology Naive B cell Antigen presentation Melanoma Experimental Cancer Treatment Priming (immunology) lcsh:Medicine Antineoplastic Agents Mice Transgenic Antigen Processing and Recognition CD8-Positive T-Lymphocytes Biology Chemoprevention Mice Cross-Priming Antigen Antigens Neoplasm Basic Cancer Research Medicine and Health Sciences Animals Antigen-presenting cell lcsh:Science Multidisciplinary Antigen processing lcsh:R Biology and Life Sciences Antigens Nuclear Tumor antigen Oncology Macrophage-1 antigen Female Clinical Immunology lcsh:Q Research Article |
| Zdroj: | PLoS ONE, Vol 9, Iss 9, p e107894 (2014) PLoS ONE |
| ISSN: | 1932-6203 |
| Popis: | Cross-presentation of tumor antigen is essential for efficient priming of naïve CD8+ T lymphocytes and induction of effective anti-tumor immunity. We hypothesized that the subcellular location of a tumor antigen could affect the efficiency of cross-presentation, and hence the outcome of anti-tumor responses to that antigen. We compared cross-presentation of a nominal antigen expressed in the nuclear, secretory, or cytoplasmic compartments of B16 melanoma tumors. All tumors expressed similar levels of the antigen. The antigen was cross-presented from all compartments but when the concentration was low, nuclear antigen was less efficiently cross-presented than antigen from other cellular locations. The efficiency of cross-presentation of the nuclear antigen was improved following chemotherapy-induced tumor cell apoptosis and this correlated with an increase in the proportion of effector CTL. These data demonstrate that chemotherapy improves nuclear tumor antigen cross-presentation and could be important for anti-cancer immunotherapies that target nuclear antigens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|